PT2145627E - Utilização de uridina em combinação com colina para o tratamento de disfunções de humor e emocionais - Google Patents

Utilização de uridina em combinação com colina para o tratamento de disfunções de humor e emocionais Download PDF

Info

Publication number
PT2145627E
PT2145627E PT91734954T PT09173495T PT2145627E PT 2145627 E PT2145627 E PT 2145627E PT 91734954 T PT91734954 T PT 91734954T PT 09173495 T PT09173495 T PT 09173495T PT 2145627 E PT2145627 E PT 2145627E
Authority
PT
Portugal
Prior art keywords
choline
uridine
treatment
mood
combination
Prior art date
Application number
PT91734954T
Other languages
English (en)
Inventor
Carol Watkins
Richard J Wurtman
Original Assignee
Massachusetts Inst Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Inst Technology filed Critical Massachusetts Inst Technology
Publication of PT2145627E publication Critical patent/PT2145627E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT91734954T 1998-07-31 1999-07-30 Utilização de uridina em combinação com colina para o tratamento de disfunções de humor e emocionais PT2145627E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9500298P 1998-07-31 1998-07-31

Publications (1)

Publication Number Publication Date
PT2145627E true PT2145627E (pt) 2014-07-24

Family

ID=22248474

Family Applications (5)

Application Number Title Priority Date Filing Date
PT100756618T PT2329829E (pt) 1998-07-31 1999-07-30 Utilização de uridina em combinação com colina para o tratamento de disfunções neurológicas
PT91734954T PT2145627E (pt) 1998-07-31 1999-07-30 Utilização de uridina em combinação com colina para o tratamento de disfunções de humor e emocionais
PT99937631T PT1140104E (pt) 1998-07-31 1999-07-30 Tratamento da doença de alzheimer, in vivo, por aumento dos níveis de citidina
PT100756600T PT2322187E (pt) 1998-07-31 1999-07-30 Utilização de uridina em combinação com colina para o tratamento de disfunções de memória
PT07116909T PT1870103E (pt) 1998-07-31 1999-07-30 Utilização de uridina em combinação com colina para o tratamento de perturbações da memória

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PT100756618T PT2329829E (pt) 1998-07-31 1999-07-30 Utilização de uridina em combinação com colina para o tratamento de disfunções neurológicas

Family Applications After (3)

Application Number Title Priority Date Filing Date
PT99937631T PT1140104E (pt) 1998-07-31 1999-07-30 Tratamento da doença de alzheimer, in vivo, por aumento dos níveis de citidina
PT100756600T PT2322187E (pt) 1998-07-31 1999-07-30 Utilização de uridina em combinação com colina para o tratamento de disfunções de memória
PT07116909T PT1870103E (pt) 1998-07-31 1999-07-30 Utilização de uridina em combinação com colina para o tratamento de perturbações da memória

Country Status (11)

Country Link
US (1) US6989376B2 (pt)
EP (5) EP1140104B1 (pt)
JP (1) JP2003517437A (pt)
AT (2) ATE446097T1 (pt)
CA (1) CA2339008C (pt)
CY (1) CY1110570T1 (pt)
DE (2) DE69937198T2 (pt)
DK (5) DK2329829T3 (pt)
ES (5) ES2332669T3 (pt)
PT (5) PT2329829E (pt)
WO (1) WO2000006174A1 (pt)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070004670A1 (en) * 1998-07-31 2007-01-04 Richard Wurtman Compositions containing citicoline, and methods of use thereof
US8314064B2 (en) * 1998-07-31 2012-11-20 Massachusetts Institute Of Technology Uridine administration stimulates membrane production
US20050203053A1 (en) * 1999-07-30 2005-09-15 Wurtman Richard J. Uridine administration improves phosphatide synthesis, synaptic transmission and cogntive function
US8518882B2 (en) * 1998-07-31 2013-08-27 Massachusetts Institute Of Technology Methods and compositions for ameliorating or inhibiting decline in memory or intelligence or improving same
US20060069061A1 (en) * 1998-07-31 2006-03-30 Dick Wurtman Compositions containing uridine and choline, and methods utilizing same
US8143234B2 (en) 1998-07-31 2012-03-27 Massachusetts Institute Of Technology Uridine administration improves phosphatide synthesis, synaptic transmission and cognitive function
US7807654B2 (en) 1998-08-31 2010-10-05 Wellstat Therapeutics Corporation Compositions and methods for treatment of mitochondrial diseases
US6472378B2 (en) * 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
US7915233B1 (en) 1998-08-31 2011-03-29 Wellstat Therapeutics Corporation Compositions and methods for treatment of mitochondrial diseases
ES2425114T3 (es) * 2000-03-16 2013-10-11 The Mclean Hospital Corporation CDP-colina y uridina para el tratamiento del abuso del acohol
US6727231B1 (en) * 2000-10-12 2004-04-27 Repligen Corporation Uridine therapy for patients with elevated purine levels
NL1019368C2 (nl) 2001-11-14 2003-05-20 Nutricia Nv Preparaat voor het verbeteren van receptorwerking.
KR20050044890A (ko) * 2002-07-11 2005-05-13 야마사 쇼유 가부시키가이샤 약제 유발성 신경장해용 의약 조성물
CN100430066C (zh) 2002-11-08 2008-11-05 麦克莱恩医院 用于烟草依赖性和戒断治疗的化合物
WO2004058160A2 (en) * 2002-12-20 2004-07-15 The Mclean Hospital Corporation Compounds for the normalization of the sleep/wake cycle
US20050113449A1 (en) * 2003-10-08 2005-05-26 Renshaw Perry F. Enhanced efficacy of omega-3 fatty acid therapy in the treatment of psychiatric disorders and other indications
JP2007508315A (ja) * 2003-10-08 2007-04-05 ザ マクレーン ホスピタル コーポレーション ω−３脂肪酸を含む組み合わせを用いて、精神障害、物質乱用障害、および他の障害を治療する方法
JP5523669B2 (ja) * 2004-05-13 2014-06-18 マサチューセッツ インスティテュート オブ テクノロジー ドーパミン放出に対するウリジンの効果
WO2005122767A1 (en) * 2004-06-10 2005-12-29 Mclean Hospital Corporation Pyrimidines, such as uridine, in treatments for patients with bipolar disorder
EP1765364A4 (en) * 2004-06-10 2010-09-22 Mclean Hospital Corp PYRIMIDINES, SUCH AS Z: B: CYTIDINE, IN THE TREATMENT OF PATIENTS WITH BIPOLAR DISORDER
EP1784199A4 (en) 2004-08-11 2010-06-23 Mclean Hospital Corp COMPOUNDS FOR TREATING MARIHUANA DEPENDENCE, DEDUCTION AND CONSUMPTION
CN102600199A (zh) * 2004-09-15 2012-07-25 麻省理工学院 含有尿苷的组合物及使用其的方法
AU2011253660B2 (en) * 2004-09-15 2013-12-19 Massachusetts Institute Of Technology Compositions containing uridine, and methods utilizing same
JP5566603B2 (ja) * 2005-05-23 2014-08-06 マサチューセッツ インスティテュート オブ テクノロジー Ｐｕｆａを含有する組成物及びそれを使用した方法
AU2012203650B2 (en) * 2005-05-23 2014-09-18 Massachusetts Institute Of Technology Compositions containing PUFA and methods of use thereof
EP1938824B1 (en) * 2005-09-22 2011-11-30 Snow Brand Milk Products Co., Ltd. Medicine, food and drink or feed containing sphingomyelin
WO2007059762A1 (de) * 2005-11-25 2007-05-31 Gisela Susilo Kombinationspräparate enthaltend physiologische zellmembran-bestandteile, einschliesslich phosphatidylserin, cholin und ein pyrimidinnukleos/tid
DK1800675T3 (da) 2005-12-23 2011-09-05 Nutricia Nv Sammensætninger omfattende polyumættede fedtsyrer, proteiner og mangan og/eller molybdæn og nucleosider/nucleotider til behandling af demens
WO2008001495A1 (fr) 2006-06-27 2008-01-03 Yamasa Corporation Agent contre les contraintes psychosociales
US7972633B2 (en) * 2007-02-07 2011-07-05 Applied Cognitive Sciences, LLC Nutritional supplements for healthy memory and mental function
WO2009059306A1 (en) * 2007-11-02 2009-05-07 Massachusetts Institute Of Technology Uridine dietary supplementation compliance methods and use thereof
US20110160158A1 (en) * 2008-06-12 2011-06-30 Repligen Corporation Methods of treatment of bipolar disorder
US20100041621A1 (en) * 2008-08-15 2010-02-18 Perry Renshaw Methods and compositions for improving cognitive performance
JP6162125B2 (ja) 2011-09-30 2017-07-12 タフツ・ユニバーシティ 神経変性障害を処置するためのウリジン二リン酸誘導体、組成物および方法
WO2013066152A1 (en) 2011-10-31 2013-05-10 N.V. Nutricia Method for improving executive function
WO2014027882A1 (en) 2012-08-13 2014-02-20 N.V. Nutricia Product and method for supporting uridine homeostasis
JP6523958B2 (ja) 2012-09-28 2019-06-05 タフツ・ユニバーシティ ウリジン二リン酸誘導体、プロドラッグ、組成物およびそれらの使用
SI2968385T1 (sl) 2013-03-13 2018-10-30 Tufts University Uridin nukleozid derivati, sestavki in metode uporabe
US10138265B2 (en) 2013-03-13 2018-11-27 Tufts University Uridine nucleoside derivatives, compositions and methods of use
WO2015115885A1 (en) * 2014-01-31 2015-08-06 N.V. Nutricia Method for reducing white matter lesions, white matter hyperintensities (wmh), leukoaraiosis or periventricular white matter disease in elderly
WO2016053085A1 (en) * 2014-09-30 2016-04-07 N.V. Nutricia Composition comprising a uridine source and butyrate producing fibres for preventing gastrointestinal disorders
WO2016072842A1 (en) * 2014-11-05 2016-05-12 N.V. Nutricia Method for preventing, reducing the risk of, or treating behavioral frontotemporal dementia
WO2017069613A1 (en) 2015-10-23 2017-04-27 N.V. Nutricia Method for improving recognition and/or working memory in hyperphenylalanimenia and phenylketonuria patients
WO2017176109A1 (en) 2016-04-04 2017-10-12 N.V. Nutricia Method for reducing or preventing global developmental delay in children
BR112020013342A2 (pt) * 2018-02-01 2020-12-01 Wellstat Therapeutics Corporation composições e dispositivos para fornecimento sistêmico de uridina
CN114990176A (zh) * 2022-05-26 2022-09-02 宁夏华吉生物有限公司 一种生产尿嘧啶核苷的方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2508474A1 (de) * 1975-02-27 1976-09-02 Boehringer Mannheim Gmbh Infusions- und spuelfluessigkeiten zur behandlung von hirnoedemen
DE2629845A1 (de) * 1976-07-02 1978-01-05 Geb Graze Erika Graze Infusions- bzw. injektionsloesungen bzw. waessrige konzentrate zu deren bereitung zur therapeutischen restituion des zellulaeren energiestoffwechsels und der koerpereigenen regelfunktion
US4221784A (en) * 1979-04-05 1980-09-09 Massachusetts Institute Of Technology Process and composition for treating disorders by administering lecithin
IT1178044B (it) * 1984-10-09 1987-09-03 Polifarma Spa Agente attivo farmaceutico per il trattamento di patologie cerebrali a base di uridina
US4609647A (en) * 1985-05-28 1986-09-02 Massachusetts Institute Of Technology Cytidyl diphosphocholine-drug composition and process
ES2007350A6 (es) * 1987-05-29 1989-06-16 Ganadera Union Ind Agro Productos alimenticios enriquecidos con nucleosidos yno nucleotidos para la nutricion infantil y de adultos, y procedimiento para su preparacion.
JP2894610B2 (ja) * 1987-10-28 1999-05-24 プロ−ニューロン，インコーポレーテッド アシル化ウリジンおよびシチジンならびにその使用
US5470838A (en) 1987-10-28 1995-11-28 Pro-Neuron, Inc. Method of delivering exogenous uridine or cytidine using acylated uridine or cytidine
IT1219667B (it) * 1988-06-21 1990-05-24 Polifarma Spa Impiego di uridina nel trattamento farmacologico di disturbi dovuti ad alterato equilibrio dopaminergico
RU2003332C1 (ru) * 1989-06-09 1993-11-30 Борис Витальевич Страдомский Средство дл лечени депрессий
JPH0722495B2 (ja) * 1990-01-30 1995-03-15 美穂 田中 クロレラ含有油脂食品
US5141943A (en) 1990-04-12 1992-08-25 Brown University Research Foundation 5-benzyl barbiturate derivatives
US5567689A (en) 1993-08-13 1996-10-22 The Uab Research Foundation Methods for increasing uridine levels with L-nucleosides
US5700590A (en) * 1994-01-10 1997-12-23 Abbott Laboratories Nutritional formula with ribo-nucleotides
JPH07215879A (ja) * 1994-02-02 1995-08-15 Otsuka Pharmaceut Factory Inc 抗ストレス組成物
DE9412374U1 (de) * 1994-08-01 1994-09-22 Rauch-Petz, Gisela G., Dr., 80803 München Nahrungsergänzungsmittel
JPH0930976A (ja) * 1995-07-17 1997-02-04 Otsuka Pharmaceut Factory Inc 記憶低下改善剤
US5843024A (en) * 1996-05-17 1998-12-01 Breonics, Inc. Solution and process for resuscitation and preparation of ischemically damaged tissue
US5962459A (en) * 1996-05-28 1999-10-05 Polifarma S.P.A. Therapeutic active agent for treatment of neuron degenerative diseases
IT1290781B1 (it) * 1996-05-28 1998-12-10 Polifarma Spa Agente attivo terapeutico per il trattamento di malattie degenerative neuronali.
US6472378B2 (en) * 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
KR100879559B1 (ko) * 1999-02-23 2009-01-22 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 미토콘드리아 장애의 치료 또는 예방용 제약조성물
JP2001233776A (ja) * 2000-02-25 2001-08-28 Yamasa Shoyu Co Ltd 学習・記憶能低下改善剤およびその用途
US20030114415A1 (en) * 2001-12-14 2003-06-19 Wurtman Richard J. Compositions and methods for treating and preventing memory impairment using citicoline

Also Published As

Publication number Publication date
EP1140104B1 (en) 2007-09-26
DE69937198T2 (de) 2008-07-03
CA2339008A1 (en) 2000-02-10
ES2294850T3 (es) 2008-04-01
ES2477568T3 (es) 2014-07-17
US20020028787A1 (en) 2002-03-07
ES2476940T3 (es) 2014-07-15
ES2332669T3 (es) 2010-02-10
WO2000006174A1 (en) 2000-02-10
EP1140104A4 (en) 2004-12-22
EP1140104A1 (en) 2001-10-10
DK2145627T3 (da) 2014-07-21
JP2003517437A (ja) 2003-05-27
EP2145627A1 (en) 2010-01-20
ATE374029T1 (de) 2007-10-15
DE69937198D1 (de) 2007-11-08
PT1140104E (pt) 2007-12-26
EP1870103A3 (en) 2008-08-06
EP2329829A2 (en) 2011-06-08
DK2329829T3 (da) 2014-07-21
CY1110570T1 (el) 2015-04-29
PT1870103E (pt) 2010-02-23
EP2329829B1 (en) 2014-04-16
US6989376B2 (en) 2006-01-24
DK1140104T3 (da) 2008-01-21
DK2322187T3 (da) 2014-07-21
EP2322187A3 (en) 2011-07-20
ES2478044T3 (es) 2014-07-18
EP2145627B1 (en) 2014-04-16
PT2322187E (pt) 2014-07-24
DK1870103T3 (da) 2010-01-11
CA2339008C (en) 2009-12-15
EP1870103A2 (en) 2007-12-26
PT2329829E (pt) 2014-07-24
DE69941586D1 (de) 2009-12-03
EP2329829A3 (en) 2011-07-20
EP1870103B1 (en) 2009-10-21
ATE446097T1 (de) 2009-11-15
EP2322187B1 (en) 2014-05-14
EP2322187A2 (en) 2011-05-18

Similar Documents

Publication Publication Date Title
PT2145627E (pt) Utilização de uridina em combinação com colina para o tratamento de disfunções de humor e emocionais
HUP0004439A3 (en) 1-substituted-1-aminomethyl-cycloalkane derivatives (=gabapentin analogues), their preparation and their use in the treatment of neurological disorders
HUP0103856A2 (hu) Gyógyszerkészítmény akut rendellenességek kezelésére
HUP0100069A2 (hu) 4(3)-Helyettesített-4(3)-aminometilpirán-, -tiopirán- vagy piperidin-származékok, a vegyületek előállítása és neurológiai rendellenességek kezelésében való alkalmazása
EP1034255A4 (en) GLRAL PRECURSORS WITH RESTRICTED LINES FROM THE CENTRAL NERVOUS SYSTEM
EP1471871A4 (en) TREATMENT OF NEUROLOGICAL DYSFUNCTIONS USING FRUCTOPYRANOSIS SULFAMATES AND ERYTHROPOIETIN
ZA965938B (en) Use of MP52 of MP121 for the treatment and prevention of diseases of the nervous system.
PL363431A1 (en) The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
HK1041827A1 (en) Compounds for the treatment of estrogen-defendent illnesses and methods for making and using the dame.
DE69318821D1 (de) Katheter zur Versorgung des Penis mit Medikamenten
HK1053264A1 (en) Phosphonate analogues of mannose-6-phosphate and their use in the treatment of wounds and fibrotic disorders.
IL142220A0 (en) Method of treating viral hemorrhagic fever
EP0592903A3 (en) Use of Ancrod in the manufacture of medications for the treatment of restenosis.
ZA978640B (en) Use of 1-hydroxy-2-pyridones for the treatment of saborrheic dermatitis.
AU4789099A (en) Therapeutic composition based on flavonoids for use in the treatment of tumours with cytotoxic agents
ZA935154B (en) Use of 1,2,5-oxadiazole-2-oxides for the treatment of erectile dysfunctions
GB9917346D0 (en) Medicament for treating premature ejaculation
IL137007A0 (en) Compounds with growth hormone releasing properties
IL139303A0 (en) Treatment of arthritis and other similar conditions
CA2197176A1 (en) Use of selegiline for the treatment of epileptic disorders
EP1081159A4 (en) PURIFIED HUMAN ACTIVIN AND PROCESS FOR PRODUCING THE SAME
ZA985818B (en) Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders.
ZA973538B (en) Use of phosphonic acid esters for the treatment of functional disorders of the brain and depression.
GB9825969D0 (en) Agents useful in the treatment of reproductive disorders
AU4486797A (en) Compositions and methods useful for the treatment of neurological and mental disorders